Inhibition of FoxO1 ameliorates hepatic steatosis and hepatitis in nonalcoholic steatohepatitis mice through regulation of gut microbiota.

Di Wen ShouYing QuanJie Min ChengSi Qi YangJia Wei ChenYong Qiang LiChen HuangHui Ting ChenYong Jian Zhou

Published in: Journal of digestive diseases (2024)

FoxO1 inhibitor AS ameliorated hepatic steatosis, inflammation, and intestinal dysbiosis in NASH mice, making it a potentially promising treatment for NASH.

Keyphrases

high fat diet induced
transcription factor
signaling pathway
oxidative stress
pi k akt
mouse model
type diabetes
adipose tissue
cell proliferation
combination therapy
replacement therapy